Results from the Atherosclerosis Risk in Communities study suggest that low serum magnesium is associated with incident kidney disease

Kidney International

Volumn 87, Issue 4, 2015, Pages 820-827

  Tin, Adrienne ^a   Grams, Morgan E ^b   Maruthur, Nisa M ^b   Astor, Brad C ^c   Couper, David ^d   Mosley, Thomas H ^e   Selvin, Elizabeth ^a   Coresh, Josef ^a   Kao, Wen Hong Linda ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d University of North Carolina at Chapel Hill   (United States)

^e UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; End stage renal disease; Magnesium; Renal failure

Indexed keywords

DIURETIC AGENT; MAGNESIUM;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; END STAGE RENAL DISEASE; ETHNICITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INCIDENTAL FINDING; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SELF REPORT; BLOOD; INCIDENCE; KIDNEY FAILURE, CHRONIC; MAGNESIUM DEFICIENCY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; UNITED STATES;

AGED; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MAGNESIUM; MAGNESIUM DEFICIENCY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; UNITED STATES;

EID: 84926516606     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.331     Document Type: Article

References (53)

1. USRDS: USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. In, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013.
2. Chronic Kidney Disease Prognosis CMatsushita K, van der Velde M et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-2081.
3. Levey AS, Coresh J. Chronic kidney disease. Lancet 2012; 379: 165-180.
4. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. Lancet 2010; 375: 1296-1309.
5. Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium status in the United States: are the health consequences underestimated? Nutr Rev 2012; 70: 153-164.
6. Ferre S, Baldoli E, Leidi M et al. Magnesium deficiency promotes a proatherogenic phenotype in cultured human endothelial cells via activation of NFkB. Biochim Biophys Acta 2010; 1802: 952-958.
7. Van Laecke S, Nagler EV, Verbeke F et al. Hypomagnesemia and the risk of death and GFR decline in chronic kidney disease. Am J Med 2013; 126: 825-831.
8. Pham PC, Pham PM, Pham PA et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 2005; 63: 429-436.
9. Sakaguchi Y, Shoji T, Hayashi T et al. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care 2012; 35: 1591-1597.
10. Holzmacher R, Kendziorski C, Michael Hofman R et al. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant 2005; 20: 1456-1462.
11. Del Gobbo LC, Imamura F, Wu JH et al. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr 2013; 98: 160-173.
12. Sakaguchi Y, Fujii N, Shoji T et al. Hypomagnesemia is a significant predictor of cardiovascular and non-cardiovascular mortality in patients undergoing hemodialysis. Kidney Int 2014; 85: 174-181.
13. Pham PC, Pham PM, Pham SV et al. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366-373.
14. Greenberg A. Diuretic complications. Am J Med Sci 2000; 319: 10-24.
15. Alves SC, Tomasi CD, Constantino L et al. Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dial Transplant 2013; 28: 910-916.
16. Van Laecke S, Van Biesen W, Vanholder R.. Hypomagnesaemia, the kidney and the vessels. Nephrol Dial Transplant 2012; 27: 4003-4010.
17. Maguire ME, Cowan JA. Magnesium chemistry and biochemistry. Biometals 2002; 15: 203-210.
18. Baldoli E, Castiglioni S, Maier JA. Regulation and function of TRPM7 in human endothelial cells: TRPM7 as a potential novel regulator of endothelial function. PLoS One 2013; 8: e59891.
19. Banai S, Haggroth L, Epstein SE et al. Influence of extracellular magnesium on capillary endothelial cell proliferation and migration. Circ Res 1990; 67: 645-650.
20. Salem S, Bruck H, Bahlmann FH et al. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol 2012; 35: 31-39.
21. Louvet L, Buchel J, Steppan S et al. Magnesium prevents phosphateinduced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 2013; 28: 869-878.
22. Kircelli F, Peter ME, Sevinc Ok E et al. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant 2012; 27: 514-521.
23. Pasch A, Farese S, Graber S et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012; 23: 1744-1752.
24. Dong JF, Cruz MA, Aboulfatova K et al. Magnesium maintains endothelial integrity, up-regulates proteolysis of ultra-large von Willebrand factor, and reduces platelet aggregation under flow conditions. Thromb Haemost 2008; 99: 586-593.
25. Ravn HB, Vissinger H, Kristensen SD et al. Magnesium inhibits platelet activity-an in vitro study. Thromb Haemost 1996; 76: 88-93.
26. Hwang DL, Yen CF, Nadler JL. Effect of extracellular magnesium on platelet activation and intracellular calcium mobilization. Am J Hypertens 1992; 5: 700-706.
27. Toft G, Ravn HB, Hjortdal VE. Intravenously and topically applied magnesium in the prevention of arterial thrombosis. Thromb Res 2000; 99: 61-69.
28. Ravn HB, Kristensen SD, Hjortdal VE et al. Early administration of intravenous magnesium inhibits arterial thrombus formation. Arterioscler Thromb Vasc Biol 1997; 17: 3620-3625.
29. Upadhyay A, Larson MG, Guo CY et al. Inflammation, kidney function and albuminuria in the Framingham Offspring cohort. Nephrol Dial Transplant 2011; 26: 920-926.
30. Hiramoto JS, Katz R, Peralta CA et al. Inflammation and coagulation markers and kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2012; 60: 225-232.
31. Shankar A, Sun L, Klein BE et al. Markers of inflammation predict the longterm risk of developing chronic kidney disease: a population-based cohort study. Kidney Int 2011; 80: 1231-1238.
32. Keller C, Katz R, Sarnak MJ et al. Inflammatory biomarkers and decline in kidney function in the elderly: the Cardiovascular Health Study. Nephrol Dial Transplant 2010; 25: 119-124.
33. Bash LD, Erlinger TP, Coresh J et al. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2009; 53: 596-605.
34. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003; 92: 10J-17J.
35. Pinkney JH, Stehouwer CD, Coppack SW et al. Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes 1997; 46(Suppl 2): S9-13.
36. Greenland P, Bonow RO, Brundage BH et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/ AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol 2007; 49: 378-402.
37. Kao WH, Folsom AR, Nieto FJ et al. Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study. Arch Intern Med 1999; 159: 2151-2159.
38. Peacock JM, Folsom AR, Arnett DK et al. Relationship of serum and dietary magnesium to incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study. Ann Epidemiol 1999; 9: 159-165.
39. Lau K. Phosphate excess and progressive renal failure: the precipitationcalcification hypothesis. Kidney Int 1989; 36: 918-937.
40. ARIC. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129: 687-702.
41. KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013; 3: 63-72.
42. Grams ME, Rebholz CM, McMahon B et al. Identification of incident CKD stage 3 in research studies. Am J Kidney Dis 2014; 64(2): 214-221.
43. Gindler EM, Heth DA. Colorimetric determination with bound "calmagite" of magnesium in human blood serum (abstract). Clin Chem 1971; 17: 662.
44. Eckfeldt JH, Chambless LE, Shen YL. Short-term, within-person variability in clinical chemistry test results. Experience from the Atherosclerosis Risk in Communities Study. Arch Pathol Lab Med 1994; 118: 496-500.
45. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
46. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604-612.
47. Matsushita K, Selvin E, Bash LD et al. Risk implications of the new CKD Epidemiology Collaboration (CKD-EPI) equation compared with the MDRD Study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010; 55: 648-659.
48. Echouffo-Tcheugui JB, Kengne AP. Risk models to predict chronic kidney disease and its progression: a systematic review. PLoS Med 2012; 9: e1001344.
49. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 update. Am J Kidney Dis 2012; 60: 850-886.
50. Tangri N, Stevens LA, Griffith J et al. A predictive model for progression of chronic kidney disease to kidney failure. JAMA 2011; 305: 1553-1559.
51. Fox CH, Mahoney MC, Ramsoomair D et al. Magnesium deficiency in African-Americans: does it contribute to increased cardiovascular risk factors? J Natl Med Assoc 2003; 95: 257-262.
52. Tian N, Penman AD, Manning RD Jr et al. Association between circulating specific leukocyte types and incident chronic kidney disease: the Atherosclerosis Risk in Communities (ARIC) study. J Am Soc Hypertens 2012; 6: 100-108.
53. Brotman DJ, Bash LD, Qayyum R et al. Heart rate variability predicts ESRD and CKD-related hospitalization. J Am Soc Nephrol 2010; 21: 1560-1570.